IMMUNOLOGICAL STUDY OF CORONARY ARTERY DISEASE ASSOCIATED WITH DIABETES MELLITUS TYPE II IN IRAQI PATIENTS

Mundher Jabbar Al-okhedi; Mohammed Qais Al-ani; Marrib N Rasheed

doi:10.22159/ajpcr.2018.v11i12.27620

Authors

Mundher Jabbar Al-okhedi Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, Iraq.
Mohammed Qais Al-ani Department of Biology, College of Science, University of Anbar, Ramadi, Iraq.
Marrib N Rasheed Department of Genetic Engineering, Institute of Genetic Engineering and Biotechnology for Post Graduate Studies, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.27620

Keywords:

Interleukin-6, Insulin-like growth factor, Coronary artery disease, Type 2 diabetes mellitus

Abstract

Objective: The objective of this study was to investigate the association between proinflammatory cytokines in special, the interleukin-6 (IL-6), and insulin-like growth factor (IGF-1) levels in coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM).

Methods: This study was conducted from November 2017 to March 2018 in Anbar, Iraq. We studied a total of 90 individuals (46 men and 44 women) aged between 20 and 87 years. The samples were divided into four groups: CAD patients (n=23), T2DM patients (n=23), coronary artery disease and type 2 diabetes together in the same patient (n=23), and control group (n=21). The concentrations of IL-6 and IGF-1 were determined using a commercially available enzyme-linked immune sorbent assay.

Results: The results of the present study showed that there were elevated serum levels of IL-6 and low levels of IGF-1 in all the tested groups, compared with the control. The difference was statistically significant at p<0.05. The results showed a positively correlated between IL-6 and IGF-1 in the CAD group and T2DM group, while it was a negative correlation between serum levels of IL-6 and IGF-1 in the T2DM+CAD group.

Conclusion: Elevated levels serum of IL-6 predicts the development of CAD and T2DM. These data support a possible role for inflammation in diabetogenesis and complication of the cardiovascular disease. There is an inverse relationship between the levels serum of IGF-1 and increased risk of CAD and development of T2DM.

Downloads

Download data is not yet available.

Author Biography

Mundher Jabbar Al-okhedi, Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, Iraq.

Biology

Mundher Jabbar AL_Okhedi

E.mail mundher_alokhedi@yahoo.com

Mobile : 00964 7813901485

Affiliation: University of Anbar-College of Education for Pure Sciences â€“ Biology Department

References

Karjalainen J. Cardiovascular Autonomic Function in Coronary Artery Disease Patients With and without Type 2 Diabetes: Significance of Physical Activity and Exercise Capacity. Finland: University of Oulu; 2013.

Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-7.

Almontashiri NA. The Genetic and Proteomic Detereminants of the Risk of Coronary Artery Disease. Doctoral Dissertation. Canada: UniversitÃ©dâ€™ Ottawa/University of Ottawa; 2015.

Nuramin HW. Effectiveness of ticagrelor compared to clopidogrel in reducing the risk of major adverse cardiovascular events in patients with coronary heart disease after percutaneous coronary intervention. Int J Pharm Pharm Sci 2016;9:178-83.

Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet 2017;389:2239-51.

Kalsi A, Singh S, Taneja N, Kukal S, Mani S. Current treatment for Type2 diabetes, their side effects and possible complementary treatments. Int J Pharm Pharm Sci 2015;3:13-8.

Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of Type 2 diabetes. N Engl J Med 2008;359:2220-32.

StenlÃ¶f K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with Type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82.

Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A, et al. Inflammatory process in Type 2 diabetes: The role of cytokines. Ann N Y Acad Sci 2006;1084:89-117.

Kishimoto T. Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8 Suppl 2:S2.

Palmqvist P, Lundberg P, Lundgren I, HÃ¤nstrÃ¶m L, Lerner UH. IL-1beta and TNF-alpha regulate IL-6-Type cytokines in gingival fibroblasts. J Dent Res 2008;87:558-63.

Niu W, Liu Y, Qi Y, Wu Z, Zhu D, Jin W. Association of interleukin-6 circulating levels with coronary artery disease: A meta-analysis implementing Mendelian randomization approach. Int J Cardiol 2012;157:243-52.

Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R, et al. Association between serum interleukin-6 concentrations and mortality in older adults: The rancho bernardo study. PLoS One 2012;7:e34218.

Pudil R, TichÃ½ M, AndrÃ½s C, RehÃ¡cek V, BlÃ¡ha V, VojÃ¡cek J, et al. Plasma interleukin-6 level is associated with NT-proBNP level and predicts short-and long-term mortality in patients with acute heart failure. Acta Medica (Hradec Kralove) 2010;53:225-8.

Omoigui S. The interleukin-6 inflammation pathway from cholesterol to aging -role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing 2007;4:1.

Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: A cross-sectional study. Cytokine 2012;57:136-42.

De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: Implications for drug design. Nat Rev Drug Discov 2002;1:769-83.

Ungvari Z, Csiszar A. The emerging role of IGF-1 deficiency in cardiovascular aging: Recent advances. J Gerontol Series A: Biomed Sci Med Sci 2012;67:599-610.

Troncoso R, DÃaz-Elizondo J, Espinoza SP, Navarro-Marquez MF, OyarzÃºn AP, Riquelme JA, et al. Regulation of cardiac autophagy by insulin-like growth factor 1. IUBMB Life 2013;65:593-601.

Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and Type 2 diabetes. Diabetes Metab Res Rev 2009;25:3-12.

Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: A prospective observational study. Lancet 2002;359:1740-5.

Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 2008;18:166-73.

Perkel D, Naghi J, Agarwal M, Morrissey RP, Phan A, Willix RD Jr, et al. The potential effects of IGF-1 and GH on patients with chronic heart failure. J Cardiovasc Pharmacol Ther 2012;17:72-8.

Braund PS. Functional Analysis of Novel Genetic Markers of Coronary Artery Disease Identified by Genome-Wide Association Studies (Doctoral dissertation, Department of Cardiovascular Sciences); 2015.

Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American heart association and the American diabetes association. Diabetes Care 2007;30:162-72.

Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with Type 2 diabetes. Cardiovasc Diabetol 2011;10:19.

Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The atherosclerosis risk in communities (ARIC) study. Ann Intern Med 2000;133:81-91.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA 2001;286:327-34.

Succurro E, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G, et al. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. Diabetes Care 2008;31:1886-8.

Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:2684-90.

De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-50.